Communiqués Sintx Technologies, Inc.

Actions

SINT

US8293927039

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 21:59:54 31/08/2026			Varia. 5j.	Varia. 1 janv.
1,520 ^USD	+1,33 %		-1,31 %	-60,88 %

11/08	Transcript : Sintx Technologies, Inc., Q2 2026 Earnings Call, Aug 11, 2026
11/08	SINTX Technologies, Inc. communique ses prévisions de chiffre d'affaires pour les troisième et quatrième trimestres 2026	CI

Communiqués

13/08	SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement	AQ
11/08	SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives	AQ
28/07	SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast	AQ
23/07	SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program	AQ
22/06	SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders	AQ
03/06	SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules	AQ
17/05	SINTX Technologies to Present at the LD Micro Invitational XVI Conference	NE
24/03	SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution	AQ
19/03	SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant	AQ
18/02	SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms	AQ
29/01	SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5	AQ
08/12	SINTX Technologies to Participate in Sidoti & Company Investor Conference	AQ
01/12	SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants	AQ
13/11	SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies	AQ
03/11	SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System	AQ
20/10/25	SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System	AQ
16/10/25	SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market	AQ
16/10/25	SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market	AQ
14/10/25	SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics	AQ
09/09/25	SINTX Technologies to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025	AQ
08/09/25	SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds	AQ
08/09/25	SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent	AQ
03/09/25	SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride	AQ
15/08/25	SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition	AQ
04/08/25	SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates	AQ